Novo Nordisk sues Eli Lilly over Wegovy vs Zepbound ads

What the lawsuit says

Novo Nordisk filed suit against Eli Lilly on July 21, 2026, in the U.S. District Court for the District of New Jersey. The complaint targets Lilly's nationwide ad campaigns for Zepbound, its obesity drug, and Mounjaro, its diabetes drug, both built on the same molecule, tirzepatide. Novo alleges the campaigns violate the Lanham Act, the federal law covering false advertising between competitors, along with several state unfair competition statutes.

The ads have been running since late April 2026. Novo's complaint puts the reach at roughly 700 million impressions. That scale is a big part of why Novo moved fast: on July 24, just three days after filing, it asked the court for a preliminary injunction to pull the ads immediately rather than wait out a normal case timeline.

The number at the center of it: 50 lbs vs 33 lbs

One Lilly TV spot cites a study showing Zepbound users lost an average of 50 lbs, compared to 33 lbs for people on Wegovy. That is the comparison Novo is suing over. Novo's complaint argues the 33-lb figure comes from the standard 2.4mg Wegovy dose, the one on the market since 2021, not the newer, stronger option.

That newer option is Wegovy HD, semaglutide at 7.2mg, which the FDA approved in March 2026 and Novo launched in April. In the STEP UP trial, we covered when it published, 7.2mg produced 20.7% mean weight loss at 72 weeks, well above the 17.5% seen at the standard 2.4mg dose in the same trial. Novo's lawsuit translates that into pounds: an average of 47 lbs lost on the higher dose, with roughly one in three participants losing about 62 lbs.

Novo does not dispute that Lilly's ad technically mentions the higher Wegovy dose. Its complaint says the mention exists only as a brief on-screen footnote, which it describes as "ambiguous, confusing, virtually illegible, and wholly inadequate" for a viewer to actually register while watching a 30-second commercial.

Eli Lilly's response

Lilly has denied wrongdoing and said it will defend the campaign. Its position, in short: the only real way to compare two drugs is a randomized, head-to-head clinical trial, and no such trial has ever pitted Zepbound against Wegovy HD directly. Absent that, Lilly says it is citing the best published data available for each drug, and that its advertising is truthful, transparent, and grounded in the most direct scientific evidence that exists today.

That is a real argument, not just a talking point. We made the same observation when Wegovy HD launched: tirzepatide at 15mg produced 20.9% weight loss in SURMOUNT-1, and semaglutide 7.2mg produced 20.7% in STEP UP, numbers close enough that the gap could plausibly vanish, reverse, or widen in an actual head-to-head trial that nobody has run. Lilly's ad picks one available comparison. Novo says it is the wrong one. Neither company can point to the trial that would resolve which one is right.

So which drug actually works better?

Nobody outside a courtroom is going to get a satisfying answer to that question this year. What is true, independent of either company's marketing: at their respective highest doses, tirzepatide and semaglutide 7.2mg land within half a percentage point of each other in separate trials with different patient populations. That is close enough that individual response, tolerability, and cost matter more than the headline weight-loss number for most people deciding between them.

Tirzepatide's dual GLP-1/GIP mechanism has a tolerability edge for some patients and different side-effect trade-offs than semaglutide. Wegovy HD introduced a side effect, dysesthesia, or altered skin sensation, in 22% of users at the 7.2mg dose that was far less common at 2.4mg. Cost and insurance coverage, including the Medicare GLP-1 Bridge that started covering both drugs in July 2026, will decide the question for a lot of people before efficacy differences do.

Why drug companies are fighting over pounds, not percentages

It is worth noticing that both the ad and the lawsuit talk in pounds, not percentages. A 50-lb claim sounds more dramatic than a 20.9% one, even when they describe the same trial result for roughly the same starting weight. Percentages are how researchers report results, because they control for body size. Pounds are how advertisers report results, because bigger numbers sell. Neither is dishonest on its own. But it is a reminder to translate any weight-loss ad claim back into a percentage of body weight before comparing it to another drug's number, since the raw pound figure depends heavily on how much weight the study population started with.

What happens next

Novo's complaint asks for a permanent injunction pulling the disputed ads and requiring Lilly to run corrective advertising. The July 24 preliminary injunction motion is the faster path, if the court grants it, the ads could come down well before the underlying case is resolved. Lilly has signaled it plans to fight both. No trial date was set as of publication, and cases like this, contested Lanham Act claims between two companies with a shared interest in a multi-billion-dollar market, often settle before reaching a jury.

This is the second front in an increasingly public rivalry. Lilly's retatrutide is already posting weight-loss numbers ahead of both drugs discussed here, and Novo has its own next-generation candidates in the pipeline. Whoever wins this lawsuit, the more durable competition is the one playing out in clinical trials, not commercials.